FindTrial
Sign In

The relationship between the genetic polymorphism of CYP2C19*2, *3 and the clinical efficacy of clopidogrel: a systematic review

The relationship between post-PCI thrombosis and the effect of CYP2C19 genetic polymorphism on clopidogrel: a systematic review

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCS-12001901
Enrollment
Unknown
Registered
2012-01-30
Start date
2011-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Case series:Nil

Sponsors

Department of Education and Science Technology, Ministry of Health
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with age at 60 and over 60; Patients had been implanted stent or intend to implanted stent; Patients are using clopidogrelor intend to use clopidogrelor; clopidogrelor have signed informed consent.

Exclusion criteria

Exclusion criteria: Patients under age 60; Patients who can not adhere to medication; Patients who can not be monitored.

Design outcomes

Primary

MeasureTime frame
drug-metabolizing enzyme polymorphisms;drug-drug interaction;adverse event;—

Contacts

Public ContactWang Yuqin
yuqwang@sina.com+86 13911881925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026